Editas Medicine, Inc. Logo

Editas Medicine, Inc.

A clinical-stage genome editing company developing CRISPR medicines for serious diseases.

EDIT | US

Overview

Corporate Details

ISIN(s):
US28106W1036
LEI:
Country:
United States of America
Address:
11 HURLEY ST., 2141 CAMBRIDGE

Description

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Editas Medicine, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Editas Medicine, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Editas Medicine, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GeneOne Life Science, Inc. Logo
Biopharmaceutical R&D company specializing in nucleic acid-based biomedicines.
South Korea
011000
Geneuro Logo
Develops therapies for neurological and autoimmune diseases by targeting HERVs.
Switzerland
GEM
GENFIT Logo
Develops therapies and diagnostics for patients with rare and severe liver diseases.
France
GNFT
GENFLOW BIOSCIENCES PLC Logo
A biotechnology company developing gene therapies that target the aging process.
United Kingdom
GENF
GENINCODE PLC Logo
Specializes in genetic risk assessment and prediction of cardiovascular disease.
United Kingdom
GENI
GENINUS Inc. Logo
A biotech company offering genomic analysis for precision medicine and drug development.
South Korea
389030
Genomed Spolka Akcyjna Logo
Biotechnology firm for genetic research and molecular diagnostics using NGS technology.
Poland
GEN
A molecular diagnostics company developing tests for the early detection of cancer.
South Korea
228760
Genomic Vision Logo
Provides DNA analysis and quality control for bioproduction and gene therapy.
France
GV
genOway Logo
Designs and develops genetically modified preclinical models for research.
France
ALGEN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.